大麻素可以减轻老年痴呆症患者的行为症状吗? 一个系统的审查
Adele Ravelli1, Chiara Ceolin1,2, Mario Virgilio Papa1
1Geriatrics Division, Department of Medicine, University of Padua, Padova, Italy.
Journal of psychopharmacology (Oxford, England)
|October 2, 2025
概括
大麻素在管理痴呆症 (BPSD) 的行为和心理症状方面表现有前途. 这一系统性审查发现,它们有效地减少了焦虑和睡眠障碍,在痴呆症护理中具有良好的耐受性和安全性.
科学领域:
- 老年学是指老年学的学科.
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 痴呆症的行为和心理症状 (BPSD) 显著影响患者和护理人员的福祉.
- 目前BPSD的管理策略存在局限性.
- 大麻素为BPSD提供了潜在的治疗途径.
研究的目的:
- 系统地审查大麻素用于管理BPSD的疗效和安全性.
- 探索在痴呆症护理中基于大麻素的干预措施的优势.
主要方法:
- 在主要数据库 (Embase,PubMed,Cochrane Library,APA PsycInfo,Web of Science) 中进行了全面的文献搜索.
- 确定了1839项研究,其中14项被选择进行全面审查.
- 研究质量使用纽卡斯尔-太华和修改后的贾达德尺度进行评估.
主要成果:
- 最终分析包括了10项涉及278名参与者的研究.
- 大麻素证明了激发的显著减少.
- 夜间干扰也受到大麻素治疗的积极影响.
结论:
- 大麻素显示承诺作为一个安全和耐受良好的选择管理BPSD在痴呆症患者.
- 有证据表明,大麻素可以缓解诸如焦虑和睡眠障碍等关键症状.
- 需要进一步的研究来巩固这些发现,并探索最佳的治疗方案.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
672
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
672
Pharmacodynamics in Geriatric Patients: Effects of Age
188
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
188
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
Drug Dosing: Geriatric Patients
227
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
227
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
782
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
782
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


